Abstract
The association of human immunodeficiency virus (HIV) and aggressive lymphomas was first reported in 1982. Before the development of effective HIV antiviral therapy, the incidence and the mortality of these lymphomas was high, with patients frequently succumbing to the disease. More lately, the combination of cART with chemoimmunotherapy significantly improved the survival outcome of the HIV-lymphomas. In this review, we discuss on describing the incidence of HIV-associated lymphomas, their clinical features, and the latest advances in the management of the various lymphoma subtypes.
Highlights
Academic Editor: Tadeusz RobakThe association of human immunodeficiency virus (HIV) and aggressive lymphomas was first reported in 1982 [1]
Diffuse large B cell lymphoma (DLBCL), Burkitt lymphoma (BL), plasmablastic lymphoma (PBL), primary DLBCL of the central nervous system (PCNS), and primary effusion lymphomas (PEL) represent the high grade B-cell lymphomas observed in persons living with HIV (PLWH), with the DLBCL and Burkitt lymphoma constituting more than 60% of the HIV-related lymphomas [9]
Were, respectively, 100% and 90% with SC-EPOCH-R and 95% and 100% with DA-EPOCH-R [42]. These results demonstrated that a low-intensity EPOCH-R-based regimen can be highly effective in HIV patients with BL [42]
Summary
The association of human immunodeficiency virus (HIV) and aggressive lymphomas was first reported in 1982 [1]. Systemic lymphomas with high grade or intermediate grade large-cell type occurring in HIV positive patients were included in the definition of the acquired immune deficiency syndrome (AIDS) [2]. Before the development of effective HIV antiviral therapy, the incidence and the mortality of these lymphomas was high, with patients frequently succumbing to the disease. HIV, their incidence decreased significantly after 1996 with the introduction of combination antiretroviral therapy (cART) [3,4]. The combination of cART with chemoimmunotherapy significantly improved the survival outcome of the HIV-lymphomas. We discuss the incidence of HIV-associated lymphomas, their clinical features, and the latest advances in the management of the various lymphoma subtypes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
